SCHEMBL8303842

SCHEMBL8303842

COC(=O)c1ccc2cc(C(C)C)[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.49
RET P07949 1/20 0.47
KDR P35968 1/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PARP1 P09874 3/20 0.46
RAB9A P51151 2/20 0.45
CREBBP Q92793 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
XDH P47989 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25787437 0.88 MEN1 (0.50) KIF11KDM4EALDH1A1MEN1KMT2A
SCHEMBL23676444 0.85 ALOX15 (0.41) RETKDR
SCHEMBL4879381 0.84 HCRTR1 (0.50) KDM4EALDH1A1MEN1KMT2ALMNA
SCHEMBL16380980 0.83 CASP3 (0.54) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL10022415 0.81 ALOX5 (0.44) RETKDRLCK
SCHEMBL5881610 0.80 KDM4E (0.61) KIF11KDM4EALDH1A1MEN1KMT2A
SCHEMBL6421763 0.80 KIF11 (0.53) KIF11KDM4EALDH1A1LMNAHTT
SCHEMBL30460215 0.80 KDM4E (0.61) KIF11KDM4EALDH1A1MEN1KMT2A
SCHEMBL7416107 0.78 KIF11 (0.46) KIF11RETKDRKDM4EALDH1A1
SCHEMBL20875018 0.78 KIF11 (0.51) KIF11KDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072598-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-07-27 US disclosed
EP-0915872-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1999-05-19 EP disclosed
WO-1998004552-A1 SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION F. HOFFMANN-LA ROCHE AG (CH) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072598-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 KIF11 4324/4885RET 810/4885KDR 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.